Genome&Company Logo

Genome&Company

Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.

314130 | KO

Overview

Corporate Details

ISIN(s):
KR7314130006
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genome & Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's core research and development programs are centered on microbiome-based pharmaceuticals, novel immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). Its primary therapeutic area is immuno-oncology, aiming to develop new treatments for various cancers. Genome & Company utilizes its proprietary drug discovery platform to advance its pipeline through clinical trials and strategic partnerships, including the out-licensing of its drug candidates to global pharmaceutical firms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 00:00
M&A Activity
주요사항보고서(타법인주식및출자증권양도결정)
Korean 20.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.4 KB
2025-08-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.3 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 77.8 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.8 KB
2025-07-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.9 KB
2025-07-10 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-07-02 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 186.7 KB
2025-07-02 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 177.1 KB
2025-06-04 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.9 KB
2025-05-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.6 KB

Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genome&Company

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genome&Company via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DONGWHA PHARM.CO.,LTD Logo
Develops, manufactures, and sells a diverse portfolio of healthcare products globally.
South Korea
000020
Dottikon ES Holding AG Logo
Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.
Switzerland
DESN
Double Bond Pharmaceutical International AB Logo
Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.
Sweden
DBP B
DR REDDYS LABORATORIES LTD Logo
Global pharma firm providing affordable generics, APIs, and medicines to patients worldwide.
United States of America
RDY
Develops & commercializes PET/CT tracers for diagnosing cancer & neurological disorders.
South Korea
176750
Dx & Vx Co., Ltd. Logo
Develops innovative diagnostics & vaccines and provides comprehensive life science contract services.
South Korea
180400
DYNAVAX TECHNOLOGIES CORP Logo
Biopharma firm developing novel vaccines, like its adult hepatitis B vaccine, with adjuvant tech.
United States of America
DVAX
Dyne Therapeutics, Inc. Logo
Developing targeted therapies for genetic neuromuscular diseases via its FORCE™ platform.
United States of America
DYN
Manufactures vet pharma for livestock/aquaculture & distributes premium pet food.
South Korea
044960
ECO ANIMAL HEALTH GROUP PLC Logo
Develops pharmaceuticals for respiratory & enteric diseases in global swine and poultry markets.
United Kingdom
EAH

Talk to a Data Expert

Have a question? We'll get back to you promptly.